首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL15 |
| Uniprot No | Q16663 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 46-113aa |
| 氨基酸序列 | SFHFAADCCT SYISQSIPCS LMKSYFETSS ECSKPGVIFL TKKGRQVCAK PSGPGVQDCM KKLKPYSI |
| 预测分子量 | 7.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL15重组蛋白的参考文献示例(注：部分信息为模拟示例，仅供参考)：
---
1. **文献名称**: *"Expression and Functional Characterization of Recombinant Human CCL15 in Inflammatory Responses"*
**作者**: Zhang Y. et al.
**摘要**: 本研究通过基因工程技术在大肠杆菌中表达并纯化了重组人CCL15蛋白，验证了其趋化活性，发现其能显著招募单核细胞和中性粒细胞。研究还探讨了CCL15在类风湿性关节炎模型中的促炎作用。
2. **文献名称**: *"CCL15/CCR1 Axis Promotes Tumor Metastasis via Modulation of Tumor Microenvironment"*
**作者**: Li H. et al.
**摘要**: 文章通过重组CCL15蛋白体外实验，证实其通过结合CCR1受体激活下游MAPK信号通路，促进肿瘤细胞侵袭和转移。研究强调了CCL15在肿瘤微环境中调控免疫逃逸的机制。
3. **文献名称**: *"Structural Insights into the Binding Mechanism of CCL15 with Glycosaminoglycans"*
**作者**: Smith J. et al.
**摘要**: 利用重组CCL15蛋白和X射线晶体学技术，解析了CCL15与硫酸肝素等糖胺聚糖的相互作用位点，揭示了其趋化功能依赖多糖结合的分子基础。
---
**备注**：以上文献信息为模拟概括，实际引用时建议通过PubMed、Web of Science等数据库检索真实文献，并核对作者、标题及摘要准确性。
**Background of CCL15 Recombinant Protein**
CCL15 (C-C motif chemokine ligand 15), also known as leukotactin-1 or MIP-5. is a member of the CC chemokine family, which plays critical roles in immune regulation, inflammation, and cell migration. It is encoded by the *CCL15* gene in humans and is primarily expressed in tissues such as the liver, lymph nodes, and intestines. CCL15 functions by binding to specific G protein-coupled receptors, including CCR1. CCR3. and CCR5. triggering intracellular signaling pathways that recruit immune cells like monocytes, lymphocytes, and eosinophils to sites of injury or infection.
As a recombinant protein, CCL15 is produced *in vitro* using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity for research applications. Recombinant CCL15 retains the ability to induce chemotaxis and modulate immune responses, making it a valuable tool for studying inflammatory diseases, cancer biology, and immune cell interactions. Its role in pathological conditions, such as rheumatoid arthritis, atherosclerosis, and tumor metastasis, has garnered significant interest. For instance, elevated CCL15 levels are associated with tumor progression in colorectal and hepatocellular cancers, where it promotes angiogenesis and immune evasion.
Despite its therapeutic potential, challenges remain in understanding its precise mechanisms and isoform-specific functions. Alternative splicing generates multiple CCL15 variants (e.g., CCL15a, CCL15b), which exhibit distinct receptor binding affinities and biological activities. Ongoing research aims to elucidate these differences and explore CCL15 as a biomarker or therapeutic target. Overall, recombinant CCL15 serves as a critical reagent for dissecting chemokine-mediated pathways and developing interventions for immune-related disorders.
×
